Trials / Available
AvailableNCT06761976
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
An Expanded Access Program to Provide Oral Sevabertinib (BAY 2927088) in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring an HER2 (Human Epidermal Growth Factor Receptor 2) Activating Mutation
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevabertinib | Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration |
Timeline
- First posted
- 2025-01-07
- Last updated
- 2026-03-30
Source: ClinicalTrials.gov record NCT06761976. Inclusion in this directory is not an endorsement.